Key Drivers
- Cash Generation
- Balance Sheet
- Dividend Coverage
AIAI Summary
FMS now looks less like a low-growth dialysis operator and more like a self-help cash-flow story driven by margin repair, reimbursement support, and capital discipline, but the key test is whether those gains can hold as U.S. treatment volumes stay weak and second-half reimbursement pressure returns.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •Cash Generation
- •Balance Sheet
- •Dividend Coverage
FMS looks steady and cash-generative at a low valuation, but higher leverage, thinner liquidity, and uneven dividend coverage are the main risks.
Price Behavior
Key Price Behavior Insights:
- •Weakening momentum
- •Support holding
- •Overhead resistance
Over the last month, FMS has rolled over from a late-July peak into a short-term downtrend, with support holding near $23.60 but resistance still overhead around $24.30–$24.40.
Late-July peak near $25.70 faded to about $23.80, signaling a sharp short-term pullback
Sentiment & News
Key News Insights:
- •Margin expansion
- •Volume weakness
- •Tariff upside
Fresenius Medical Care is showing better profitability and margin expansion, but softer U.S. treatment volumes, flat revenue trends, and reimbursement headwinds keep the outlook cautious despite some policy-driven upside.
The stock may stay pressured near term unless U.S. treatment volumes improve and revenue growth re-accelerates
Similar Companies in Healthcare
Other companies in the same sector with AI ratings